Barry Singer
Neurology · Saint Louis, MONPI 1932210671
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2019 at $495,818 and has fallen 52.9% since, to $233,439 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,713 payments — averaging $1135.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$394K
- EMD Serono, Inc.$255K
- Sanofi$247K
- TG Therapeutics, Inc.$203K
- Genentech USA, Inc.$177K
- Novartis$154K
- plus $515K from 30 others
Across 227 payments — averaging $6305.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$641K
- Sanofi$298K
- Novartis$210K
- TG Therapeutics, Inc.$163K
- Biogen$57K
- Alkermes, Inc.$27K
- plus $35K from 3 others
What the payments were for
- Consulting fees$625,88032%
- Speaking & faculty fees$1,069,91555%
- Grants$61,2753%
- Travel & lodging$151,3338%
- Food & beverage$34,1562%
- Education$1,9760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 268 | $393,513 |
| EMD Serono, Inc. | 181 | $254,667 |
| Sanofi | 151 | $247,194 |
| TG Therapeutics, Inc. | 123 | $203,318 |
| Genentech USA, Inc. | 155 | $176,565 |
| Novartis | 333 | $153,952 |
| E.r. Squibb & Sons, L.L.C. | 63 | $87,745 |
| Bristol Myers Squibb | 111 | $73,036 |
| AstraZeneca | 62 | $71,382 |
| Sanofi-aventis U.S. LLC | 14 | $62,729 |
| Novartis Pharma AG | 14 | $44,552 |
| Hoffmann-la Roche Limited | 11 | $43,339 |
| Johnson & Johnson | 26 | $31,535 |
| AbbVie(2 entities) | 63 | $13,235 |
| Amgen(2 entities) | 32 | $12,088 |
| Hexal AG | 3 | $11,700 |
| Teva Pharmaceuticals USA, Inc. | 16 | $11,288 |
| Merck Kgaa | 5 | $8,770 |
| Vanda Pharmaceuticals Inc. | 7 | $8,412 |
| Ares Trading SA | 2 | $8,215 |
| Greenwich Biosciences, Inc. | 2 | $8,100 |
| Genentech, Inc. | 5 | $6,150 |
| Sanofi US Services Inc. | 1 | $5,763 |
| Bayer | 2 | $4,014 |
| Cycle Pharmaceuticals Inc | 2 | $2,264 |
| Acadia Pharmaceuticals Inc | 15 | $287 |
| Pfizer | 23 | $214 |
| Lilly USA, LLC | 6 | $128 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Supernus Pharmaceuticals, Inc. | 3 | $67 |
| Lundbeck LLC | 2 | $57 |
| Acorda Therapeutics, Inc | 3 | $55 |
| Banner Life Sciences, LLC | 2 | $53 |
| MDD US Operations, LLC | 2 | $41 |
| Mylan Specialty L.p. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$192,479
- Vumerity$189,153
- OCREVUS$180,316
- Mavenclad$178,298
- AUBAGIO$116,965
- ZEPOSIA$114,324
- LEMTRADA$87,597
- TYSABRI$82,328
- MAYZENT$60,780
- KESIMPTA$37,350
- TECFIDERA$35,880
- SOLIRIS$32,798
- ARZERRA$32,618
- Ozanimod$32,291
- Ponvory$21,410
- Ocrevus Zunovo$15,328
- GILENYA$14,084
- NO PRODUCT DISCUSSED$12,486
- UPLIZNA$11,681
- COPAXONE$9,090
How this compares
$1,944,533 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 184 | $1,678,454 |
| MayzentSiponimod | 67 | $842,559 |
| RebifInterferon Beta-1a/Albumin | 47 | $698,651 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 40 | $642,891 |
| AubagioTeriflunomide | 34 | $552,113 |
| VumerityDiroximel Fumarate | 52 | $511,481 |
| CopaxoneGlatiramer Acetate | 51 | $459,776 |
| Teriflunomide | 213 | $360,558 |
| TecfideraDimethyl Fumarate | 26 | $239,324 |
| FingolimodFingolimod Hcl | 54 | $183,421 |
| GilenyaFingolimod Hcl | 14 | $134,262 |
| Glatiramer Acetate | 56 | $126,006 |
| Aimovig AutoinjectorErenumab-Aooe | 147 | $126,003 |
| GlatopaGlatiramer Acetate | 57 | $111,900 |
| Nurtec OdtRimegepant Sulfate | 59 | $83,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent, Gilenya | $153,952 | $976,82181 claims |
| BiogenVumerity, Tecfidera | $393,513 | $750,80678 claims |
| EMD Serono, Inc.Rebif | $254,667 | $698,65147 claims |
| SanofiAubagio | $247,194 | $552,11334 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $11,288 | $459,77651 claims |
| AbbVieUbrelvy, Qulipta | $13,235 | $115,063104 claims |
| PfizerNurtec Odt, Dilantin | $214 | $88,63281 claims |
| Upsher-smith Laboratories LLCTopiramate | $17 | $2,969148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in Saint Louis
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
- Jameson HollomanSaint Louis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.